NCT02629523View on ClinicalTrials.gov

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

May 11, 2020

Conditions
Lung NeoplasmsEGFR Gene Mutation
Interventions
DRUG

Afatinib

Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.

Trial Locations (1)

58128

Chonnam National University Hwasun Hospital, Hwasun

All Listed Sponsors
lead

Chonnam National University Hospital

OTHER

NCT02629523 - Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA | Biotech Hunter | Biotech Hunter